Global Neglected Tropical Diseases Drugs And Vaccines Market Size study, by Product (Drugs, Vaccines), by Disease (Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya), and Regional Forecasts 2022-2032

Global Neglected Tropical Diseases (NTDs) Drugs and Vaccines Market is valued at approximately USD 2.07 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.00% during the forecast period 2024 to 2032. Addressing the global health gap, the NTDs drugs and vaccines market emerges as a crucial force in combating diseases long sidelined due to socioeconomic inequalities and infrastructural shortcomings. Affecting more than a billion people globally, these infections—such as leishmaniasis, dengue, lymphatic filariasis, and chikungunya—are prevalent in low-income, tropical, and subtropical regions. Governments, philanthropic bodies, and global health agencies are amplifying efforts to eradicate these preventable illnesses through collaborative R&D pipelines and equitable distribution models for effective pharmaceutical interventions.

The resurgence of research interest in neglected tropical diseases is being propelled by a combination of public-private partnerships, WHO-backed roadmaps, and emerging innovations in vaccine technology. Biopharmaceutical enterprises are increasingly leveraging mRNA platforms, adjuvant combinations, and recombinant protein technologies to develop next-gen vaccines for these diseases. Meanwhile, drug development efforts are benefiting from AI-driven molecule screening and improved genomic insights into pathogens, enabling targeted therapeutics with fewer side effects. However, the demand is not just about discovery—it’s about scalable access. Initiatives such as the Drugs for Neglected Diseases initiative (DNDi) and GAVI-led immunization drives underscore the urgency of creating affordable, shelf-stable formulations suited to fragile health ecosystems.

Despite momentum, the market still contends with structural and logistical hurdles. Fragmented supply chains, limited cold chain infrastructure, regulatory complexities, and insufficient return on investment have traditionally constrained commercial interest in this sector. Moreover, the ever-evolving nature of tropical disease outbreaks, coupled with emerging resistance to antiparasitic drugs, introduces additional uncertainty. Nevertheless, stakeholder collaboration is intensifying, and multi-sectoral alliances are now integrating diagnostics, therapeutics, and vaccines under comprehensive disease eradication strategies. The rising global focus on pandemic preparedness has also placed neglected diseases under the broader spotlight of health security, incentivizing long-term funding and cross-border cooperation.

From a product perspective, both vaccines and therapeutics are expected to maintain strong demand, with vaccines gaining traction as preventive medicine in outbreak-prone regions. Drug interventions remain essential for chronic or recurring infections like leishmaniasis and filariasis. Market players are adopting modular production techniques, heat-stable packaging, and novel oral administration routes to suit low-resource settings. The growing convergence of field-based clinical trial networks and digital health technologies is enabling real-time epidemiological surveillance, data-driven resource allocation, and faster regulatory approvals across endemic geographies.

Regionally, Latin America and Sub-Saharan Africa remain the most impacted and are thus central to the market’s growth trajectory. Brazil, Kenya, Nigeria, and India represent key hotspots where disease burden intersects with public health innovation and donor-funded intervention frameworks. Asia Pacific—particularly India and Southeast Asia—is accelerating vaccine R&D with the support of biotech clusters and WHO collaborations. North America and Europe, though lower in endemicity, continue to play pivotal roles as innovation hubs and funding powerhouses, driving the global supply chain of NTD medicines and vaccines. Multilateral efforts like the London Declaration and UN Sustainable Development Goals are expected to sustain long-term momentum and funding alignment.

Major market player included in this report are:
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• Sanofi S.A.
• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• Cipla Limited
• Eisai Co., Ltd.
• Cadila Pharmaceuticals
• Serum Institute of India Pvt. Ltd.
• BioE (Biological E. Limited)
• Bharat Biotech International Limited
• PATH
• MedinCell SA

The detailed segments and sub-segmens of the market are explained below:

By Product
• Drugs
• Vaccines

By Disease
• Lymphatic Filariasis
• Echinococcosis
• Leishmaniasis
• Dracunculiasis
• Dengue
• Chikungunya

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.